WE DISCOVER AND DEVELOP NOVEL AND
DIFFERENTIATED THERAPIES IN CANCER AND BEYOND
ADDRESS UNMET MEDICAL NEEDS FOR PATIENTS IN CHINA AND GLOBALLY
Founded in 2016, we have established a robust in-house R&D engine underpinned by an oustanding discovery team and multi-dimensional discovery platform. We have strategically designed and developed a rich pipeline of 10+ small molecule programs focused on oncology.
Founders
Our exceptional discovery and development capability are driven by the experienced and visionary founders with prolific track records in having led or made contributions to over 50 drug discovery programs.
Consists of a broad range of small-molecule
precision-oncology and immuno-oncology product candidates
We have established and continue to explore broad partnership
and collaboration with industry and academic leaders
News & Press
3 September, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announced do...
12 July, 2020, Shanghai—bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announces that it ...
Shanghai, Beijing, Hong Kong, July5th, 2021, bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd.(“Abbisko”) has entered in...
29 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announced dosing...
4 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announced the app...
4 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) announced the appointme...
We aspire to become a leading biopharmaceutical company to discover and develop novel and differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.
Since our establishment, we have completed four rounds of financing led by blue-chip investors. Our investor base is a testament to our capabilities and provides strong financial supports and industry insights to our future success.
Copyright © 2021 All rights reserved:Abbisko Therapeautics 沪ICP备17056565号-1
